MARKET

AARD

AARD

Aardvark Therapeutics
NASDAQ
4.010
+0.240
+6.37%
Opening 14:39 04/01 EDT
OPEN
3.800
PREV CLOSE
3.770
HIGH
4.080
LOW
3.770
VOLUME
304.67K
TURNOVER
--
52 WEEK HIGH
17.94
52 WEEK LOW
3.350
MARKET CAP
87.48M
P/E (TTM)
-1.3665
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at AARD last week (0323-0327)?
Weekly Report · 2d ago
Analysts Conflicted on These Healthcare Names: Cytokinetics (CYTK), Aardvark Therapeutics, Inc. (AARD) and Incyte (INCY)
TipRanks · 03/25 10:30
U.S. RESEARCH ROUNDUP-Amazon, Diamondback Energy, Matador Resources
Reuters · 03/25 08:01
AARDVARK THERAPEUTICS INC <AARD.O>: JONESTRADING CUTS TARGET PRICE TO $19 FROM $33
Reuters · 03/25 03:41
Aardvark Therapeutics price target lowered to $8 from $32 at B. Riley
TipRanks · 03/24 12:42
AARDVARK THERAPEUTICS INC <AARD.O>: B. RILEY CUTS TARGET PRICE TO $8 FROM $32
Reuters · 03/24 12:40
RBC Capital Sticks to Its Hold Rating for Aardvark Therapeutics, Inc. (AARD)
TipRanks · 03/24 11:36
Aardvark Therapeutics Price Target Maintained With a $9.00/Share by BTIG
Dow Jones · 03/24 11:09
More
About AARD
Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. The Company targets biological pathways associated with alleviating hunger that has the potential to deliver transformative outcomes for patients. It is focused on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its initial compounds target TAS2Rs expressed in the gut lumen, which normally respond to the nutrients in food and participate in the gut-brain axis. Its wholly owned lead product candidate, ARD-101 (denatonium acetate monohydrate), is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which it has initiated a Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome (PWS).

Webull offers Aardvark Therapeutics, Inc. stock information, including NASDAQ: AARD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AARD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AARD stock methods without spending real money on the virtual paper trading platform.